Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BLFS
HOLDBioLife Solutions, Inc. · Healthcare · United States · $1.5B · Avg Vol: $44M/d
COMPANY DESCRIPTION
BioLife Solutions, Inc. provides proprietary biopreservation media, thawing devices, and cloud-based cold chain management solutions for the cell and gene therapy markets. As a market leader, its proprietary media and thawing technologies are becoming industry standards for cell and gene therapy clinical trials and commercialization, creating significant customer stickiness. The company serves nearly all major cell and gene therapy clinical trials globally.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 76.2M | 68.0M | 74.6M | 96.2M | 8.1% | 101.7M | 114.0M | 134.6M | 18.3% |
| EPS | -3.29 | -1.55 | -0.44 | -0.09 | — | -0.24 | — | — | — |
| Shares | 42.8M | 45.2M | 46.9M | 48.2M | +12.5% | 48.9M | — | — | — |
| Debt | 43.7M | 33.8M | 30.0M | 17.9M | -25.7% | 14.9M | — | — | — |
| Equity | 364.2M | 337.7M | 348.9M | 371.9M | 0.7% | — | — | — | — |
| Op CF | -8.5M | -12.5M | 8.4M | 20.1M | 138.6% | 17.9M | — | — | — |
| Inv CF | -58.1M | 17.8M | 58.3M | -71.5M | — | — | — | — | — |
| Fin CF | 16.3M | 10.6M | -6.8M | -10.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BLFS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BLFS | BioLife Solutions, Inc.(you) | $1.5B | 56 | HOLD |
| STAA | STAAR Surgical Company | $1.2B | 56 | HOLD |
| ATRC | AtriCure, Inc. | $1.8B | 48 | HOLD |
| AZTA | Azenta, Inc. | $1.3B | 44 | HOLD |
| ANGO | AngioDynamics, Inc. | $562M | 58 | HOLD |
| LMAT | LeMaitre Vascular, Inc. | $2.2B | 75 | BUY |
| XRAY | DENTSPLY SIRONA Inc. | $2.6B | 73 | BUY |
| WRBY | Warby Parker Inc. | $3.0B | 41 | HOLD |
| KMTS | Kestra Medical Technologies, Ltd. | $1.2B | 21 | SELL |
| AVTR | Avantor, Inc. | $7.8B | 62 | HOLD |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.5%